ArticleFrontiers in medicine2026
Assessment of biochemical and hematological profiles in outpatients with serological evidence of SARS-CoV-2 infection.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SARS-CoV-2 infection is known to induce systemic biochemical and hematological alterations, particularly in hospitalized patients. However, data regarding subclinical changes in ambulatory, non-hospitalized individuals-especially in Latin American populations-remain limited. Objective: To compare biochemical and hematological parameters between ambulatory adults with and without serological evidence of prior SARS-CoV-2 infection, in order to identify potential subclinical alterations associated with previous virus exposure. Methods: A cross-sectional study was conducted in 201 ambulatory adults from central-northern Mexico between August and December 2020. Anti-SARS-CoV-2 IgG and IgM antibodies were detected using two independent lateral flow immunochromatographic assays. Participants were classified as seropositive only when both assays showed concordant reactivity. Biochemical and hematological parameters were compared between seropositive and seronegative individuals using appropriate parametric or non-parametric tests. Results: Overall seroprevalence of anti-SARS-CoV-2 antibodies was 22.3%. No significant differences were observed in hematological parameters between seropositive and seronegative participants. In contrast, seropositive individuals exhibited significantly lower high-density lipoprotein cholesterol (HDL-C) levels compared to seronegatives (median: 40.5 vs. 45.3 mg/dL; Conclusion: Even mild or asymptomatic SARS-CoV-2 infection is associated with subtle but consistent alterations in lipid metabolism and liver enzymes in ambulatory, unvaccinated individuals. These findings support the need for biochemical monitoring after SARS-CoV-2 infection, particularly in populations with high baseline cardiometabolic risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.